Development of a Sulfadoxine-Pyrimethamine Tablet, for IPTp

We would like to draw your attention to a new request for information (RFI) issued by MMV on 20 April, closing on 12 May 2017.
 
As part of a programme to improve access to malaria chemoprevention commodities, MMV is supporting the aims of national malaria programmes in endemic countries to reduce the number of deaths from malaria suffered by pregnant women and their unborn babies. The only regimen currently approved by WHO is that of Intermittent Preventive Treatment in Pregnancy (IPTp) consisting of full curative doses of treatment with sulfadoxine and pyrimethamine (SP) during pregnancy. 
 
To date, no SP product has been approved that specifically targets IPTp or has received WHO pre-qualification. Therefore, part of MMV’s strategy to support IPTp is to gain an understanding the current status of manufacturing capacity for SP (including sulfadoxine and pyrimethamine APIs) and any plans and/or interest on the part of manufacturers to produce, obtain WHO pre-qualification, and to market a presentation pack specifically for IPTp to improve the uptake in malaria-endemic countries. We invite interested parties to help us to understand what gaps and barriers may exist currently to bringing a WHO pre-qualified SP tablet to the market for IPTp use, by responding to this RFI.